(ClinicalTrials.gov number: NCT03488485) Disclosures: Radha Dhiman: Nothing to Disclose, Madhumita Premkumar: Nothing to Disclose, Jasvinder Nain: Nothing to Disclose, Ajay Duseja: Nothing to Disclose, EkTA Gupta: Nothing to Disclose, Sahaj Rathi: Nothing to Disclose, SUNIL TANEJA: Nothing to Disclose, Surender Singh: Nothing to Disclose, Akash Roy: Nothing to Disclose, Anchal Sandhu: Nothing to Disclose, Prerna Sharma: Nothing to Disclose, Gagandeep Singh Grover: Nothing to Disclose 2622 CLINICAL AND GENETIC CHARACTERISTICS OF PATIENTS WITH HISTOLOGIC STEATOSIS DEFINED BY NATURAL LANGUAGE PROCESSING IN THE MVP LIVER BIOPSY COHORT Samiran Mukherjee 1 Patrick Alba 2 Anthony Gao 3 Craig Teerlink 3 David Kaplan 4 K Rajender Reddy 4 Tia Dinatale 3 Timothy Morgan 5 Saiju Pyarajan 6 Daniel Dochtermann 6 Marijana Vujkovic 1 Julie Lynch 3 Kyong-Mi Chang 1 , 1 Philadelphia VAMC, UPenn, 2 VINCI, 3 VINCI, VA Salt Lake City, 4 University of Pennsylvania, 5 VA Long Beach Healthcare System, 6 VA Boston Healthcare System Background: Metabolic-Associated Steatotic Liver Disease (MASLD) is a leading cause of chronic liver disease (CLD)

Alterations of the microvascular network in the sclerotic hippocampus of patients with temporal lobe epilepsy
When you pair a nutrient-dense diet with a high-quality, bioavailable supplement, you are giving your body the best possible tools for cellular protection
These commercial relationships do not influence the factual content or editorial integrity of the information provided, which is based on scientific literature, clinical understanding, and established biochemical mechanisms